Category: Regions

May 23, 2017 Off

Novo Nordisk submits application in the US for label addition for its diabetes drug

By Dino Mustafić

Novo Nordisk has submitted a supplemental application to the US Food and Drug Administration (FDA) for including data in the label for Tresiba (insulin degludec) from the DEVOTE trial, a long-term, randomised, double-blinded and event-driven trial conducted to confirm the cardiovascular safety of Tresiba compared to insulin glargine U100 when added to standard of care, in people with type 2 diabetes.

Anavex presents new data for certain neuro-diseases tratment
May 22, 2017 Off

Anavex presents new data for certain neuro-diseases tratment

By Dino Mustafić

Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain, and various types of cancer, has announced new preclinical data for ANAVEX 2-73 in the neurodevelopmental disorders Angelman syndrome, Fragile X syndrome and Rett syndrome.

Arix bags $65 million in a B series investment round
May 19, 2017 Off

Arix bags $65 million in a B series investment round

By Dino Mustafić

Arix Bioscience on Friday said that its new business group, Iterum, has raised $65 million by closing a Series B investment round. “Arix is delighted to have led this $65m funding round comprising many of the biotech sector’s leading specialist investors,” said…

argenx raises approximately $100 million gross proceeds
May 18, 2017 Off

argenx raises approximately $100 million gross proceeds

By Dino Mustafić

argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today the pricing of its initial public offering in the United States with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS.

Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test
May 18, 2017 Off

Oxford BioDynamics subsidiary signs exclusive Asia licence for breast cancer test

By Dino Mustafić

Oxford BioDynamics’s subsidiary Oxford BioDynamics Pte Limited, has signed an exclusive licence agreement with Nova Satra Diagnostics Asia Limited, to supply its proprietary products and reagents for the potential use in a non-invasive blood test to assist in the diagnosis of breast cancer, in complementation to current breast cancer screening procedures, across 13 territories in Asia.